AR042480A1 - Derivados de la quinazolina para el trtamiento del crecimiento celular anormal - Google Patents

Derivados de la quinazolina para el trtamiento del crecimiento celular anormal

Info

Publication number
AR042480A1
AR042480A1 ARP030104645A ARP030104645A AR042480A1 AR 042480 A1 AR042480 A1 AR 042480A1 AR P030104645 A ARP030104645 A AR P030104645A AR P030104645 A ARP030104645 A AR P030104645A AR 042480 A1 AR042480 A1 AR 042480A1
Authority
AR
Argentina
Prior art keywords
alkyl
group
formula
quinazoline
derivatives
Prior art date
Application number
ARP030104645A
Other languages
English (en)
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of AR042480A1 publication Critical patent/AR042480A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente se refiere a procedimientos de tratamiento del crecimiento celular anormal en mamíferos mediante la administración de los compuestos de fórmula (1), y a composiciones farmacéuticas para tratar dichos trastornos que contienen los compuestos de fórmula (1), y a procedimientos de preparación. Reivindicación 1: Un compuesto caracterizado porque es de fórmula (1) o una sal, solvato o profármaco farmacéuticamente aceptable del mismo, en la que: R1 se selecciona del grupo constituido por H, y alquilo C1-6; R2 se selecciona del grupo constituido por H, grupos alquilo C1-10, alcoxi C1-6 e hidroxialquilo C1-6; R3 se selecciona del grupo constituido por H, alquilo C1-6, hidroxialquilo C1-6 y C(O)OR4, estando seleccionado R4 del grupo constituido por H y alquilo C1-6; R5 se selecciona del grupo constituido por -C(O)OH y -(CR6R7)m-NR1R8, en la que m es un número entero de 0 a 3; cada R6 y R7 está independientemente seleccionado del grupo constituido por H y alquilo C1-6, y en la que R8 se selecciona del grupo constituido por alquilo C1-6 y -C(O)-(CR6R7)m-O(alquilo C1-6); y en la que el compuesto de fórmula (1) está opcionalmente sustituido además con un hidroxi o un sustituyente ácido O-glucurónico.
ARP030104645A 2002-12-18 2003-12-16 Derivados de la quinazolina para el trtamiento del crecimiento celular anormal AR042480A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US43448602P 2002-12-18 2002-12-18

Publications (1)

Publication Number Publication Date
AR042480A1 true AR042480A1 (es) 2005-06-22

Family

ID=32595280

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP030104645A AR042480A1 (es) 2002-12-18 2003-12-16 Derivados de la quinazolina para el trtamiento del crecimiento celular anormal

Country Status (20)

Country Link
US (1) US20040254204A1 (es)
EP (1) EP1575592A1 (es)
JP (1) JP2006513179A (es)
KR (1) KR20050085749A (es)
CN (1) CN1729001A (es)
AR (1) AR042480A1 (es)
AU (1) AU2003303045A1 (es)
BR (1) BR0317433A (es)
CA (1) CA2510323A1 (es)
GT (1) GT200300286A (es)
MX (1) MXPA05006335A (es)
NL (1) NL1025044C2 (es)
NO (1) NO20053483L (es)
PA (1) PA8592801A1 (es)
PE (1) PE20040905A1 (es)
PL (1) PL377686A1 (es)
RU (1) RU2005119172A (es)
TW (1) TW200424190A (es)
WO (1) WO2004054585A1 (es)
ZA (1) ZA200504147B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2491191C (en) 2002-07-15 2014-02-04 Exelixis, Inc. Receptor-type kinase modulators and methods of use
RU2328287C2 (ru) * 2003-08-18 2008-07-10 Пфайзер Продактс Инк. Схема приема erbb2 противоопухолевых агентов
ES2925655T3 (es) 2003-09-26 2022-10-19 Exelixis Inc Moduladores c-Met y métodos de uso
EP1896451A2 (en) * 2005-06-03 2008-03-12 Pfizer Products Incorporated Bicyclic derivatives for the treatment of abnormal cell growth
US8236823B2 (en) 2006-10-27 2012-08-07 Amgen Inc. Multi-cyclic compounds and methods of use
TWI447108B (zh) 2009-01-16 2014-08-01 Exelixis Inc Ｎ－（４－｛〔６，７雙（甲氧基）喹啉－４－基〕氧基｝苯基）－ｎ’－（４－氟苯基）環丙烷－１，１－二甲醯胺之蘋果酸鹽及其結晶型
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
US9526648B2 (en) 2010-06-13 2016-12-27 Synerz Medical, Inc. Intragastric device for treating obesity
US8628554B2 (en) 2010-06-13 2014-01-14 Virender K. Sharma Intragastric device for treating obesity
US10010439B2 (en) 2010-06-13 2018-07-03 Synerz Medical, Inc. Intragastric device for treating obesity
US10420665B2 (en) 2010-06-13 2019-09-24 W. L. Gore & Associates, Inc. Intragastric device for treating obesity
EP2621481B2 (en) 2010-09-27 2022-10-19 Exelixis, Inc. Dual inhibitors of met and vegf for the treatment of castration-resistant prostate cancer and osteoblastic bone metastases
US10779980B2 (en) 2016-04-27 2020-09-22 Synerz Medical, Inc. Intragastric device for treating obesity

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0711783A1 (en) * 1994-11-08 1996-05-15 Glaxo, S.A. Antifungal Sordarin derivatives
UA71945C2 (en) * 1999-01-27 2005-01-17 Pfizer Prod Inc Substituted bicyclic derivatives being used as anticancer agents
WO2001021596A1 (en) * 1999-09-21 2001-03-29 Astrazeneca Ab Quinazoline derivatives and their use as pharmaceuticals
WO2001053290A1 (fr) * 2000-01-18 2001-07-26 Nippon Steel Corporation Inhibiteurs de la division cellulaire et procede de production de ces inhibiteurs
AP2001002192A0 (en) * 2000-06-22 2002-12-21 Pfizer Prod Inc Substituted bicyclic derivatives for the treatment of abnormal cell growth.
ATE377009T1 (de) * 2001-11-30 2007-11-15 Osi Pharm Inc Verfahren für die herstellung substituierter bicyclischer derivate zur behandlung von anomalem zellwachstum
CN1602195A (zh) * 2001-12-12 2005-03-30 辉瑞产品公司 用于治疗异常细胞生长的喹唑啉衍生物
IL161915A0 (en) * 2001-12-12 2005-11-20 Pfizer Prod Inc Salt forms of methoxy-N-(3-(4-(3-methyl-pyridin-3-yloxyl)-phenylamino)- quinazolin-6-yl)-allyl)-acetamide, its prepar

Also Published As

Publication number Publication date
EP1575592A1 (en) 2005-09-21
PA8592801A1 (es) 2004-07-26
BR0317433A (pt) 2005-11-16
GT200300286A (es) 2004-08-13
NO20053483L (no) 2005-09-19
JP2006513179A (ja) 2006-04-20
PE20040905A1 (es) 2005-01-18
NL1025044A1 (nl) 2004-06-21
RU2005119172A (ru) 2006-01-20
WO2004054585A1 (en) 2004-07-01
NO20053483D0 (no) 2005-07-18
KR20050085749A (ko) 2005-08-29
AU2003303045A1 (en) 2004-07-09
US20040254204A1 (en) 2004-12-16
CN1729001A (zh) 2006-02-01
TW200424190A (en) 2004-11-16
PL377686A1 (pl) 2006-02-06
MXPA05006335A (es) 2005-08-26
CA2510323A1 (en) 2004-07-01
NL1025044C2 (nl) 2005-02-15
ZA200504147B (en) 2006-07-26

Similar Documents

Publication Publication Date Title
PE20221910A1 (es) Derivados de pirazolilo utiles como agentes anticancerigenos
AR041566A1 (es) Derivados de indol utiles para el tratamiento de enfermedades
AR042480A1 (es) Derivados de la quinazolina para el trtamiento del crecimiento celular anormal
AR045143A1 (es) Compuestos de indazol 3,5- distribuidos, composiciones farmaceuticas y metodos para intervenir en o inhibir la proliferacion celular
RU2203274C2 (ru) Спироциклические ингибиторы металлопротеаз
AR043111A1 (es) Derivados monoacilados de o-fenilendiaminas
AR055303A1 (es) Derivados de triazol sustituidos como antagonistas de oxitocina, composicion farmaceutica y uso del compuesto para preparar un medicamento
BR0317435A (pt) Derivados de pirimidina para o tratamento do crescimento celular anormal
ECSP024393A (es) Derivados biciclicos sustituidos para el tratamiento del crecimiento celular normal
AR046297A1 (es) Inhibidores de la dpp - iv metodos para prepararlos y composiciones farmaceuticas que los contienen como agente activo
EA200500174A1 (ru) Новые производные бензимидазола, полезные в качестве антипролиферативных агентов
EA200100135A1 (ru) Алкинилзамещенные производные хинолин-2-она, полезные в качестве противораковых агентов
EA200702339A1 (ru) Замещенные амидные производные в качестве ингибиторов протеинкиназы
WO2016069578A1 (en) Bromodomain inhibitors
CO5721006A2 (es) Derivados de pirazolo-quinazolina, proceso para su preparacion y su uso como inhibidores de quinasa
NO20072115L (no) Farmasoytiske forbindelser
AR058287A1 (es) Derivados de isoquinolina y composicion farmaceutica
WO2008012635A3 (en) Amine derivatives useful as anticancer agents
AR024060A1 (es) Nuevos compuestos farmaceuticamente activos
KR940701264A (ko) 안과질환에 대한 마크로라이드 화합물의 용도
ECSP045073A (es) Nuevos derivados de piperazina
UY39032A (es) Compuestos heterocíclicos como agentes antivirales
AR057576A1 (es) Derivados sustituidos de pirrolidin-quinazolinas inhibidores de canales de sodio dependientes de voltaje, composiciones farmaceuticas que los contienen y usos, entre otros, en el tratamiento de una variedad de condiciones de dolor
NO20061357L (no) Chelerytrin, analoger derav og deres anvendelse i behandling av bipolare, forstyrrelser og andre koginitive forstyrrelser
AR072802A1 (es) Derivados piperidinicos de esteres de acido bifenil-2-il-carbamico, antagonistas de receptores muscarinicos m3, composiciones farmaceuticas que los contienen y usos de los mismos para el tratamiento de trastornos digestivos,respiratorios y/o urinarios.

Legal Events

Date Code Title Description
FB Suspension of granting procedure